Background. Early screening for syphilis among pregnant women and the effective treatment of maternal syphilis is fundamental to prevent congenital syphilis (CS).
Maternal syphilis remains a global public health problem worldwide with an estimated 930 000 pregnant women infected in 2012 [1] . Untreated or inadequately treated syphilis infections among pregnant women can lead to adverse pregnancy outcomes, including early fetal deaths, stillbirths, prematurity, low birthweight, neonatal death, and congenital syphilis (CS), in >50% of cases [2, 3] . It was estimated that there were 350 000 adverse pregnancy outcomes caused by maternal syphilis globally [1] . Because of its recognized adverse pregnancy outcomes and public health problems, CS has been targeted by the World Health Organization (WHO) for elimination in global initiatives via the reduction of the prevalence of syphilis in pregnant women and by the prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) and syphilis since 2007 [4, 5] .
CS is a preventable disease, which can be eliminated through effective antenatal screening programs and treatment of infected pregnant women [4, 6] . Evidence demonstrates that antenatal care interventions for syphilis in the first 2 trimesters of pregnancy can significantly reduce the risk of having an adverse outcome due to maternal syphilis [7, 8] . Therefore, adequate treatment for syphilis in early pregnancy is a critical component of CS prevention. Multiple countries that have a high burden of maternal and CS report stockouts and shortages of penicillin [9] . On the other hand, some countries such as China recommend providing 2 courses of benzathine penicillin injection in the first and third trimesters [10, 11] . Here, we aim to report the risk of developing CS among infants born to mothers with different treatment scenarios of maternal syphilis during pregnancy in Shenzhen, China.
METHODS

Participants
The Shenzhen Program for Prevention of CS (SPPCS) was a citywide program supported by the Bureau of Health (now the Health and Family Planning Commission) of Shenzhen Municipality. The program was initiated in July 2002, covering 90 antenatal clinics (ANCs) including 52 public clinics and 38 private clinics in the city, and since 2011 has been merged into the National Integrated Program for PMTCT of HIV, Syphilis and Hepatitis B [12] . Cohorts of pregnant women were structured by data drawn from master datasets to include pregnant women who were identified with syphilis seroposivity at their first antenatal visit and had information on their treatment status for syphilis. The pregnant women finally included for analyses were limited to those women whose infants had a definite outcome of confirming or excluding a diagnosis of CS by October 2016 (Table 1) .
Definition and Treatment of Syphilis-Seropositive Pregnant Women
ANCs covered by the PMTCT program offered a free syphilis screening with the toluidine red unheated serum test (TRUST; Shanghai Rongsheng BioTech Co, Ltd, Shanghai, China), a standard nontreponemal test equivalent to the rapid plasma reagin and approved by the US Centers for Disease Control and Prevention (CDC) [13] , as a routine antenatal service to all pregnant women at their first visit to the clinics. Samples positive for syphilis screening were confirmed by a treponemal test of Treponemal pallidum particle agglutination (TPPA; Fujirebio Inc, Tokyo, Japan). Those samples with positive TRUST further underwent a quantitative/ titer TRUST testing for monitoring response to treatment. Syphilis-seropositive pregnant women were defined as having both positive TRUST and positive TPPA according to the national guidelines [14] .
Intramuscular benzathine penicillin G (BPG) was applied as the first choice to all syphilis-seropositive pregnant women regardless of the disease stage for at least 1 course (2.4 million units of BPG once weekly for 3 consecutive weeks). A second course of treatment during late pregnancy had been applied in the study area before it was recommended by the national PMTCT guidelines in 2012. Procaine penicillin G (PPG) 0.8 million units intramuscularly once daily for 15 days was introduced during [2003] [2004] [2005] [2006] [2007] [2008] . Pregnant women who were allergic to penicillin were treated with erythromycin 500 mg orally 4 times a day for 15 days, azithromycin 500 mg orally once a day for 10 days, or ceftriaxone sodium 1 g injection per day for 10 days.
Based on treatment status prior to the current pregnancy, the syphilis-seropositive pregnant women were categorized into group 1 (adequate treatment before pregnancy) or group 2 (no treatment before pregnancy). Each of the groups was further grouped into (1) treatment with early BPG (initiation of BPG or PPG before 28 weeks of gestation); (2) treatment with late BPG (initiation of BPG or PPG at ≥28 weeks of gestation); (3) treatment with other antibiotics; or (4) no treatment during pregnancy. We used the term of BPG to represent both BPG and PPG (Figure 1 ).
Diagnosis and Treatment of Congenital Syphilis
All infants born to syphilis-seropositive pregnant women were evaluated for clinical evidence (eg, rash, condyloma lata, syphilitic rhinitis) and microbiological evidence of CS. Dark-field microscopy was conducted if any indicative lesions occurred. Serum samples were collected from all infants born to syphilis-seropositive pregnant women immediately after delivery and tested for TPPA, 19S-IgM-TPPA (Euroimmun Medizinische Labordiagnostika AG, Lubeck, Germany), TRUST, and TRUST titer if it was positive. Further serological follow-up of the infants who were born to syphilis-seropositive pregnant women but undiagnosed with CS at delivery was conducted every 3 months to monitor any changes in TRUST titer and TPPA positivity. Diagnosis of CS (probable or confirmed case) was based on meeting 1 of the following laboratory criteria: (1) a reactive 19S-IgM-TPPA; (2) a serum quantitative TRUST titer that was 4-fold higher than the mother's titer; (3) a ≥4-fold rise in TRUST titer during the follow-up; or (4) a reactive TPPA that did not revert to nonreactive by end of 18 months of follow-up. Stillbirth potentially due to syphilis was not accounted for as cases of CS. Infants with reactive TPPA and/or TRUST that reverted to both nonreactive TPPA and TRUST for 2 consecutive follow-up tests were identified as CS-free and excluded from the follow-up cohort. All infants diagnosed with CS were treated with aqueous crystalline penicillin according to the national guidelines [10, 14] .
Statistical Analysis
The primary outcome of interest was incidence of CS among infants born to syphilis-seropositive women. We calculated the crude incidence and its 95% confidence interval (CI). If a pregnant woman delivered >1 infant, data on the woman were used for evaluating each of her infants. We accounted for potential confounding variables (see list of characteristics in Table 1) in association between the rate of CS and treatment regimen by using multivariate logistic regression models to estimate adjusted odds ratios (aORs) and their 95% CIs. We further used multivariate logistic regression to assess characteristics associated with the odds of having no treatment for maternal syphilis during pregnancy. For all analyses, P values <.05 were regarded as statistically significant. Statistical analysis was done using SPSS for Windows (version 16.0, SPSS Inc, Chicago, Illinois) and MedCalc for Windows (version 16.8, Mariakerke, Belgium) software.
For use of the SPPCS dataset for the current study, we obtained an additional ethical review and approval from the committee (approval number 2016NL021).
RESULTS
Cohort of Pregnant Women
Between 1 January 2003 and 31 December 2014, 3 087 672 pregnant women were screened for syphilis and 9617 were identified to be seropositive for syphilis, giving a seroprevalence of 0.31% (95% CI, .30%-.32%). The pregnancies of 2110 women were terminated because of spontaneous abortions before 28 weeks of pregnancy (n = 334 [15.8%] ), stillbirths at ≥28 gestational weeks (n = 204 [9.7%]), ectopic pregnancies (n = 597 [28.3%]), and artificial abortions or inductions (n = 975 [46.2%]). A total of 7448 pregnant women for whom treatment information was available were enrolled. Of these women, 1678 (22.5%) had syphilis and were adequately treated with at least 1 course of intramuscular BPG before pregnancy. Excluding 889 (11.9%) women who were lost to follow-up, mostly because of migration (76.1%), 6559 pregnant women delivered 6584 infants to be enrolled as a cohort for evaluation of CS. Of these infants, 27.9% were lost from the cohort mainly because of migration of their parents (66.9%) before CS could be excluded or before the end of 18 months of follow-up. Finally, 4746 matched data of mothers and their infants were included for analyses. Based on records of the adequate treatment before pregnancy and the treatment status during pregnancy, the data were categorized into 6 treatment subgroups-3 subgroups each for women with and without adequate treatment prior to pregnancy (Figure 1 ). The baseline characteristics were not different across the groups without treatment prior to pregnancy, although we identified <1 years in mean age between the cohorts (Table 1) .
Relative Risk of Congenital Syphilis by Treatment Regimen
There were 2624, 591, 62, and 1469 infants born to mothers treated with early BPG, late BPG, other antibiotics (85.5% with erythromycin), and untreated, respectively. A total of 162 infants were diagnosed with CS (including 100, 5, 9, and 6 cases meeting criteria 1, 2, 3, and 4, respectively, and 42 cases meeting both criteria 1 and 2), giving an overall incidence of 3.41% (95% CI, 2.91%-3.98%). Among infants born to syphilis-seropositive pregnant women who were adequately treated before pregnancy, the incidence of CS was 0.22% (95% CI, .05%-.66%). Among these women, the disease occurred more frequently among infants born to mothers who were not re-treated for syphilis during the current pregnancy (0.63% [95% CI, .08%-2.29%]) than those who were re-treated (0.10% [95% CI, 0-.55%), corresponding to a risk difference of 0.53% (95% CI, 0-1.13%), but the difference was not statistically significant (P > .05).
There were 159 cases of CS occurring in 3519 infants born to women who were newly diagnosed with seropositivity during the current pregnancy, giving an incidence of CS of 4.52% (95% CI, 3.84%-5.28%). Of the 159 cases, 6, 11, 1, and 141 occurred in infants born to the women treated with early BPG, late BPG, or other antibiotics and those without any treatment, respectively. As shown in Table 2 (Table 4) .
DISCUSSION
During the years of 2003-2014, we identified 0.31% of women infected with syphilis in our area, which was similar to that reported in many countries (ie, 0.30% in Costa Rica, 0.32% in Bangladesh, and 0.35% in Moldova), but lower than the global estimate of 0.66% [1] . The cohort of >7000 syphilis-seropositive pregnant women and their infants in our study was an order of magnitude larger than previously published cohorts [15] [16] [17] . The size of the cohort together with the long period of follow-up allowed us to explore the risk of CS in infants born to syphilis-seropositive pregnant women. The study provides a complete ascertainment of the risk of developing CS across infants born to the women treated with different regimens. WHO has proposed a set of laboratory criteria for surveillance case definition of CS [18] .The presence of a ≥4-fold titer of nontreponemal antibody or a specific immunoglobulin M (IgM) in the infant at delivery is strongly suggestive of congenital infection [19, 20] , but the absence of the evidence does not exclude congenital infection due to poor performance of these assays [21] [22] [23] . Serial serologic follow-up of infants born to seropositive mothers who are not diagnosed with CS at birth are needed. Because the passively transferred maternal nontreponemal antibody titer usually declines by 3 and is negative by 6 months in noninfected infants or after effective treatment for CS but the transferred treponemal antibodies can persist for 12-15 months [6, 24] , a reactive treponemal test after age 18 months is diagnostic of CS [6] . In our study, a reactive treponemal test by end of 18 months of follow-ups of infants born to syphilis-seropositive mothers was used as one of the criteria for the diagnosis of CS to increase the sensitivity of diagnosis.
Our study estimated that 12.23 of 100 infants born to mothers with untreated syphilis developed CS, which is consistent with the pooled estimate (15.5%) from a systematic review and meta-analysis including 6 observational studies from African countries [3] . However, the rate was obviously higher than that reported after 1990 in Zambia (2.2%) [25] or Tanzania (4.1%) [26] and lower than the rate of 50.8% from the Web-based reporting system in Shanghai, China [15] . However, the high rate in Shanghai has been considered to be a result of misdiagnosis of CS in health facilities and overreporting of the cases to the reporting system [27] .
To successfully prevent CS and other adverse pregnancy outcomes from maternal syphilis, WHO recommends the treatment of all seropositive women with at least 1 dose of BPG or an alternative effective regimen before the end of the first trimester [18] . United Kingdom guidelines recommend a single dose of BPG when treatment is initiated in the first or second trimester and 2 doses of BPG given 1 week apart when treatment is initiated in the third trimester [28] . CDC guidelines indicate an insufficiency of evidence to determine the optimal penicillin treatment regimen for maternal syphilis but list treatment with a second dose of BPG 1 week after the initial dose for women with early syphilis as a management option [6] . The national guidelines for PMTCT of syphilis in China suggest 2 courses of BPG [29] . The findings from our study showed that the incidence of CS among women treated with 1 course was not significantly different from those with 2 courses, indicating that an additional course did not significantly enhance efficacy and further supporting the WHO recommendation of a single dose of BPG for prevention of CS. We had 40 seropositive women treated with antibiotics other than penicillin (mostly erythromycin for those women allergic to penicillin). However, the small sample size was unlikely to have a substantial effect on our estimate of the risk difference in comparison with those treated with penicillin.
CDC guidelines recommend that pregnant women with stable, serofast low antibody titers who have previously been treated for syphilis might not require additional treatment. It has been reported that women are more likely to be serofast compared with men because of differences in the immune system [30] . In our cohort, we identified 22.5% of pregnant women seropositive for syphilis who had been adequately treated before pregnancy but we could not categorize them into reinfection, serological nonresponse, or serofast status as we were not able to obtain accurate information on sexual behaviors related to the reinfection after the previous treatment. However, the incidence rates of CS between those re-treated and not re-treated during pregnancy are comparable, suggesting that the women who were adequately treated for syphilis before pregnancy do not need additional treatment during pregnancy. However, treatment should be considered if the women cannot provide a clear treatment record to document adequate treatment or have ongoing risk of reinfection after the previous treatment. Undergoing early syphilis screening tests at the first antenatal visit of pregnancy, followed by prompt and adequate treatment of seropositive women with BPG, is at the center of CS prevention. The definitions of "early" treatment compared with "late" treatment varied across the studies [15, [31] [32] [33] [34] . CDC defines adequate treatment as completion of a penicillin-based regimen, in accordance with CDC treatment guidelines, initiated ≥30 days before delivery [35] . Our study took a cutoff point of 28 gestational weeks to compare women receiving treatment before or after this date and showed a significantly lower incidence of CS among women who received the treatment before 28 weeks compared with treatment after 28 weeks or no treatment. CS was 8.06 times more common in women treated after 28 weeks and 68.28 times more in women untreated compared with those given treatment before 28 gestation weeks.
Our study had several limitations. First, our study was limited by ethical restrictions on the use of a randomized controlled trial design that evaluates a treatment intervention from a control group. Current retrospective design may result in potential bias across the groups with different treatment regimens. Second, small sample sizes in the group treated with antibiotics rather than BPG limited the statistical power for comparing this group with BGP groups. Third, stillbirths attributable to maternal syphilis were absent from the criteria of CS, potentially resulting in an underestimation of risk to develop CS, particularly among the group of women who were untreated for maternal syphilis. In settings with moderate to high maternal syphilis prevalence, CS has been reported to account for >20% of all stillbirths [26, 36] . Fourth, high rates of loss to follow-up may bias the estimation of CS in some subgroups.
In conclusion, our findings provide an update on the risks of developing CS in infants born to women with treated and untreated maternal syphilis, suggesting that early treatment of maternal syphilis with single course of intramuscular 2.4 MU BPG before gestational week 28 is critical for preventing CS. In addition, re-treatment of seropositive women who were adequately treated for syphilis prior to pregnancy does not significantly further reduce the risks of developing CS. These findings are expected to be used as evidence for guiding our practice to prevent mother-to-child transmission of syphilis and for updating the WHO-developed tools for estimating the disease burden of adverse pregnancy outcomes due to maternal syphilis [1] .
Notes
